Compare Abbott Laboratories (ABT) vs IAC/Interactivecorp (PPLI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs IAC/Interactivecorp — how do they compare? Abbott Laboratories trades at $95.16 (market cap $166.94B), while IAC/Interactivecorp trades at $46.74 (market cap $3.54B). The key difference: Abbott Laboratories is far larger — about 47.2× IAC/Interactivecorp's market cap, and Abbott Laboratories pays a 2.63% dividend while IAC/Interactivecorp pays none. Which is the better fit depends on your goals.
| ABT | PPLI | |
|---|---|---|
Market Cap | $166.94B | $3.54B |
Sector | Health | Media |
52-Week High | $136.62 | $47.62 |
52-Week Low | $82.57 | $31.52 |
Enterprise Value | $193.69B | $3.85B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.18, down 0.47% on the day, with a bullish technical signal and strong analyst consensus. The stock shows solid fundamentals with a P/E of 26.85, net income margin of 13.91%, and consistent dividend payments. Recent news highlights CE Mark approval for Libre Duo systems and positive diagnostic portfolio developments, supporting growth prospects in healthcare markets.
Outlook remains positive with a consensus price target of $122.55 implying 29% upside, though risks include competitive pressures and macroeconomic volatility. Earnings beat in Q1 2026 offsets prior misses, while cash flow stability and declining debt-to-asset ratio (15.02% in 2025) reinforce financial health. Institutional sentiment is strongly bullish with 75.6% buy ratings.
PPLI trades at $47.62, up 1.86% today, showing bullish technical momentum with moving averages supporting the uptrend. However, the stock has missed earnings expectations for three consecutive quarters, with Q1 2026 EPS of -$0.94 falling short of the -$0.37 estimate. Despite a high gross margin of 66.49%, net income margin remains thin at 1.75%, and cash flow turned negative in 2025 with a net outflow of $820.42 million. Analyst consensus remains positive with a $55.40 price target, though recent news questions valuation after a rally.
The outlook is mixed: strong analyst buy ratings and a discounted P/B of 0.77 suggest upside potential, but persistent earnings misses and negative cash flow pose significant risks. Revenue decline from $5.2B in 2022 to $2.4B in 2025 highlights operational challenges. Investors should weigh the bullish technical setup against fundamental weaknesses and high debt levels before committing capital.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →
